Association of the vitamin D receptor genotype with bone metastases in breast cancer patients

Oncology

Volumn 64, Issue 2, 2003, Pages 154-159

  Schöndorf, Thomas ^a   Eisberg, Carsten ^a   Wassmer, Gernot ^b   Warm, Mathias ^a   Becker, Martina ^a   Rein, Daniel T ^a   Göhring, Uwe Jochen ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c Johanniter Krankenhaus   (Germany)

Author keywords

Bisphosphonates; Bone metastasis; Polymorphisms; Vitamin D receptor

Indexed keywords

ENDONUCLEASE; VITAMIN D RECEPTOR;

ADULT; AGAR GEL ELECTROPHORESIS; ALLELE; ARTICLE; BONE DENSITY; BONE METASTASIS; BREAST CANCER; CANCER PATIENT; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; EXON; FEMALE; GENE AMPLIFICATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; RESTRICTION SITE; STATISTICAL ANALYSIS;

BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RECEPTORS, CALCITRIOL;

EID: 0037268935     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067767     Document Type: Article

References (26)

1. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, Lowen D, Javni J, Miller FR, Slavin J, Anderson RL: A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 1999;17:163-170.
2. Mundy GR: Mechanisms of bone metastasis. Cancer 1997;80:1546-1556.
3. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339:357-363.
4. Koyama T, Hasebe T, Tsuda H, Hirohashi S, Sasaki S, Fukutomi T, Imoto S, Umeda T, Mukai K: Histological factors associated with initial bone metastasis of invasive ductal carcinoma of the breast. Jpn J Cancer Res 1999;90: 294-300.
5. Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, Kanis JA, Kyle RA, Mundy GR, Paterson AHG, Rubens RD: Current use of bisphosphonates in oncology. J Clin Oncol 1998;16:3890-3899.
6. Issa LL, Leong GM, Eisman JA: Molecular mechanism of vitamin D receptor action. Inflamm Res 1998;47:451-475.
7. Boyce BF, Yoneda T, Guise TA: Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer 1999;6:333-347.
8. Kato S: The function of vitamin D receptor in vitamin D action. J Biochem 2000;127:717-722.
9. Langub MC, Reinhardt TA, Horst RL, Malluche HH, Koszewski NJ: Characterization of vitamin D receptor immunoreactivity in human bone cells. Bone 2000;27:383-387.
10. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eisman JA: Prediction of bone density from vitamin D receptor alleles. Nature 1994;367:284-287.
11. Lundin AC, Söderkvist P, Eriksson B, Bergman-Jungeström M, Wingren S, South East Sweden Breast Cancer Group: Association of breast cancer progression with a vitamin D receptor gene polymorphism. Cancer Res 1999;59:2332-2334.
12. Ruggerio M, Pacini S, Aterini S, Fallai C, Ruggerio C, Pacini P: Vitamin D receptor gene polymorphism is associated with metastatic breast cancer. Oncol Res 1998;10:43-46.
13. Ingles SA, Garcia DG, Wang W, Nieters A, Henderson BE, Kolonel LN, Haile RW, Coetzee GA: Vitamin D receptor genotype and breast cancer in Latinas (United States). Cancer Causes Control 2000;11:25-30.
14. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991;19:403-410.
15. Love RR: Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Clin Oncol 2002;20:879-880.
16. Dunning AM, Mc Bride S, Gregory J, Durocher F, Foster NA, Healey CS, Smith N, Pharoah RN, Luben RN, Easton DF, Ponder BAJ: No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer. Carcinogenesis 1999;20:2131-2135.
17. Curran JE, Vaughan T, Lea RA, Weinstein SR, Morrison NA, Griffiths LR: Association of a vitamin D receptor polymorphism with sporadic breast cancer development. Int J Cancer 1999;83:723-726.
18. Carling T, Kindmark A, Hellman P, Holmberg L, Åkerström G, Rastad J: Vitamin D receptor allelesb, aandT:Risk factors for sporadic primary hyperparathyroidism (HPT) but not HPT of uremia or MEN 1. Biochem Biophys Res Comm 1997;231:329-332.
19. McClure L, Eccleshall TR, Gross C, Villa ML, Lin N, Ramaswamy V, Kohlmeier L, Kelsey JL, Marcus R, Feldman D: Vitamin D receptor polymorphisms, bone mineral density, and bone metabolism in postmenopausal Mexican-American women. J Bone Miner Res 1997;12:234-240.
20. Need AG, Horowitz M, Stiliano A, Scopacasa F, Morris HA, Chatterton BE: Vitamin D receptor genotypes are related to bone size and bone density in men. Eur J Clin Invest 1996; 26:793-796.
21. Sainz J, Van Tornout JM, Loro ML, Sayre J, Roe TF, Gilsanz V: Vitamin D-receptor gene polymorphisms and bone density in prepubertal American girls of Mexican descent. N Engl J Med 1997;337:77-82.
22. Vandevyver C, Wylin T, Cassiman JJ, Raus J, Geusens P: Influence of the vitamin D receptor gene alleles on bone mineral density in postmenopausal and osteoporotic women. J Bone Miner Res 1997;12:241-247.
23. Elomaa I, Blomqvist C, Grohn P, Porkka L, Kariento AL, Selander K, Lamberg-Allardt C, Holmstrom T: Long-term controlled trial with diphosphonates in patients with osteolytic bone metastases. Lancet 1983;i:146-149.
24. Diel IJ, Mundy GR: Bisphosphonates in the adjuvant treatment of cancer: Experimental evidence and first clinical results. International Bone and Cancer Study Group (IBCG). Br J Cancer 2000;82:1381-1386.
25. Diel IJ, Solomayer EF, Bastert G: Bisphosphonates and the prevention of metastasis. Cancer 2000;88(suppl):3080-3086.
26. Saarto T, Blomqvist C, Virkkunen P, Elomaa II: Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001;19:10-17.